Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.

WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration to widen access to advanced care throughout central Pennsylvania, US.

The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for Eli Lilly’s Onswik (efsitora alfa) in a move that opens the insulin jab up for national ...

Tanabe’s dersimelagon is already under FDA review having achieved positive Phase III results earlier this year.

Ultragenyx Pharmaceutical has received accelerated approval from the FDA for its gene therapy, Genglycos, to treat GSDIa.

Kynexis will now prepare for registrational studies on lead asset, KYN-5356 in cognitive impairment associated with schizophrenia (CIAS).

Faeth Therapeutics has received fast track designation from the FDA for the PIKTOR with paclitaxel combination to treat advanced or recurrent endometrial cancer.

The FDA has granted accelerated approval to BMS' Zenbexus, along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma.

Andelyn Biosciences is set to develop and manufacture a gene therapy known as AAV9-GM2, for Queen’s University to treat GM2 gangliosidoses, including Tay-Sachs and Sandhoff diseases.

Fulcrum Therapeutics and Slate Medicines have signed a definitive agreement to merge in an all-stock transaction backed by a $245m private placement financing from a syndicate of healthcare investors.

BeOne Medicines, the BeOne Care Foundation, and The Max Foundation have extended their Brukinsa access programme for CLL until 2028.

Phanes Therapeutics has received fast track designation from the US FDA for spevatamig to treat patients with advanced and metastatic BTC.